A collaboration led by PATH have published an update on previous work evaluating the potential economic and public health impact of vaccines effective against Shigella, an increasingly antibiotic-resistant bacteria that remains a significant cause of diarrheal disease morbidity and mortality. Researchers used the WHO’s Full Value of Vaccine Assessment analytic framework and formulated five broad scientific, policy, economic and commercial-related propositions regarding the development of a Shigella vaccine. They also explored the current regulatory, clinical, policy and commercial challenges to a Shigella-containing combination vaccine development and adoption.
As described in a series of separate publications that are synthesized here, authors concluded that the economic and public health value of a Shigella vaccine may be greater than previously recognized, particularly if it is found to also be effective against less severe forms of diarrheal disease and childhood stunting. The decision by pharmaceutical companies to develop a standalone vaccine or a multi-pathogen combination will be a key factor in determining its relative prioritization by various stakeholders in low- and middle-income countries.
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.